Stifel Maintains Buy on Sionna Therapeutics, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

Stifel analyst Paul Matteis maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $44 to $55.